Site menu

Search by ticker code:
Generic filters

Menu

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

5 fastest growth shares on the ASX: PME, HUB, PNV, CDA & MAQ

What are the five fastest growth shares on the ASX? Pro Medicus Ltd (ASX: PME), HUB24 Limited (ASX: HUB), Polynovo Ltd (ASX: PNV), Codan Limited (ASX: CDA) and Macquarie Technology Group (ASX: MAQ) top the list, but let me explain...

What are the five fastest growth shares on the ASX? Pro Medicus Ltd (ASX: PME), HUB24 Limited (ASX: HUB), Polynovo Ltd (ASX: PNV), Codan Limited (ASX: CDA) and Macquarie Technology Group (ASX: MAQ) top the list, but let me explain…

Earlier today, in the first Rask Invest LIVE show (see below), I showed how any investor can use a tool like Tikr.com to quickly and easily identify top performing shares on the ASX, based solely on fundamentals (e.g. financial data, stock price performance, etc.). It starts around 38 minutes.

I need to be really careful when I say this but using technology tools and historical financials alone is not a worthwhile investment strategy. It won’t work.

When you’re investing in ASX shares (or US stocks), you don’t get market-thumping returns using the same tools, data and inputs as everyone else.

After all, if you do the average thing in investing… you’ll get average results… less taxes and costs.

Why? Companies can be tracked using historical quantitative results (e.g. sales and profits) because they use qualitative inputs (employees, customers, marketing and value proposition) and mix them together.

Put another way, anyone can run a one-minute analysis on stock data using Tikr to see that Pro Medicus has been the best ASX share over the past 10 years. But identifying Pro Medicus 10 years ago – before it had a huge run up in sales of its Visage product to US radiologists – was the secret. That type of research is hard and substantially qualitative.

Top 5 ASX growth shares

Nonetheless, if you’re looking for growth shares that have a history of strong performance, which you’ll then pursue for further research, here’s a list of top ASX growth shares over 10 years (excluding banks, resources, and tiny speculative shares):

  1. Pro Medicus – 15,258% share price return
  2. HUB24 – 5,062% share price return
  3. Polynovo – 2,133% share price return
  4. Codan – 1,649% share price return
  5. Macqaurie Technology Group – 1,520% share price return

Obviously, Pro Medicus is a clear standout winner.

I’ve been grateful to own Pro Medicus shares for many years – along with many Rask members and readers who have heard us talk about to co-founder and CEO Sam Hupert or read our original Buy research back in 2017. Pro Medicus is a medical software business, providing industry-leading software for hospitals and radiologists.

HUB24 is also very interesting.

Alongside Netwealth Ltd (ASX: NWL) and Macquarie Group (ASX: MQG), HUB is probably Australia’s leading financial and investment admin software, used by financial planners, accountants and fund managers. It has undertaken acquisitions but the real growth has been organic, as more advisers pushed their clients onto HUB’s platform so that their life (i.e. the adviser’s) is made easier.

Finally, earlier this month I dived into Polynovo for our community members and podcast listeners. Even though it’s outside my circle of competence, it’s been an All Star company. But after many years of hype, Polynovo has seen a pullback recently.

Is this a turning point for Polynovo? You decide…

Is Polynovo Ltd (ASX:PNV) the next Pro Medicus (ASX:PME)?

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Owen owns shares of Pro Medicus.
Skip to content